Imricor Medical Systems Inc (ASX:IMR)

Full Year 2024 Imricor Medical Systems Inc Earnings Call Transcript

Feb 26, 2025 / 10:00 PM GMT

Release Date Price: A$1.46 (-11.52%)

Transcript

Key Points

Positve

Imricor Medical Systems Inc (ASX:IMR) achieved significant regulatory progress in Europe and the US, including CE mark approval for their diagnostic catheter and second-generation ablation catheter.
The company is in the early stages of global commercialization, expanding its footprint and unlocking value for patients and physicians worldwide.
Imricor Medical Systems Inc (ASX:IMR) reported a 56% increase in total revenues for the year, driven by double-digit growth in both equipment and consumable revenues.
The company has successfully attracted high-caliber talent to its sales team, significantly expanding its pipeline and progress towards new hospital adoption.
Imricor Medical Systems Inc (ASX:IMR) is pioneering MRI-guided cardiac ablations, which promise faster, more successful procedures at lower costs and with improved safety.

Negative

The net loss for the period was $29.7 million, an increase of 31% from the prior year, driven by the fair value change of convertible notes and warrants.
Some European sites are exclusively enrolling patients in non-revenue generating trials to support FDA approval, impacting immediate revenue generation.
The company faces challenges in the regulatory approval process, with some aspects beyond their control, potentially affecting timelines.
Imricor Medical Systems Inc (ASX:IMR) has not yet initiated efforts to enter the Asia Pacific markets, including mainland China, despite recognizing its potential.
The company is still in the process of gaining FDA approval for its Northstar system and other products, which could delay commercialization in the US.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

IMR.AX - Imricor Medical Systems Inc
Full Year 2024 Imricor Medical Systems Inc Earnings Call
Feb 26, 2025 / 10:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Over to Steve to go through the presentation. I'll just remind you that you can submit a question through the Q&A button at the bottom of your Zoom screen, or alternatively the for analysts, you can raise your hand and allow you to talk your question. Steve, I'll hand it over to you now, thank you.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
All right, thanks, Simon.

Hello everyone, thank you for joining us today to discuss the report's full year results for 2024. For those new to our story, ERCO is the global leader in designing and

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.